@phdthesis{Hoecker2022,
  author    = {H{\"o}cker, Julian Harald},
  title     = {High-quality Organolead Trihalide Perovskite Crystals: Growth, Characterisation, and Photovoltaic Applications},
  doi       = {10.25972/OPUS-25859},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-258590},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2022},
  abstract  = {Overview of the Organolead Trihalide Perovskite Crystal Area Studies of perovskite single crystals with high crystallographic quality is an important technological area of the perovskite research, which enables to estimate their full optoelectronic potential, and thus to boost their future applications [26]. It was therefore essential to grow high-quality single crystals with lowest structural as well as chemical defect densities and with a stoichiometry relevant for their thin-film counterparts [26]. Optoelectronic devices, e.g. solar cells, are highly complex systems in which the properties of the active layer (absorber) are strongly influenced by the adjacent layers, so it is not always easy to define the targeted properties and elaborate the design rules for the active layer. Currently, organolead trihalide perovskite (OLTP) single crystals with the structure ABX3 are one of the most studied crystalline systems. These hybrid crystals are solids composed of an organic cation such as methylammonium (A = MA+) or formamidinium (A = FA+) to form a three-dimensional periodic lattice together with the lead cation (B = Pb2+) and a halogen anion such as chloride, bromide or iodide (X = Cl-, Br- or I-) [23]. Among them are methylammonium lead tribromide (MAPbBr3), methylammonium lead triiodide (MAPbI3), as well as methylammonium lead trichloride (MAPbCl3) [62, 63]. Important representatives with the larger cation FA+ are formamidinium lead tribromide (FAPbBr3) and formamidinium lead triiodide (FAPbI3) [23, 64]. Besides the exchange of cations as well as anions, it was possible to grow crystals containing two halogens to obtain mixed crystals with different proportions of chlorine to bromine and bromine to iodine, as it is shown in Figure 70. By varying the mixing ratio of the halogens, it was therefore possible to vary the colour and thus the absorption properties of the crystals [85], as it can be done with thin polycrystalline perovskite films. In addition, since a few years it is also doable to grow complex crystals that contain several cations as well as anions [26, 80, 81]. These include the perovskites double cation - double halide formamidinium lead triiodide - methylammonium lead tribromide (FAPbI3)0.9(MAPbBr3)0.1 (FAMA) [26, 80] and formamidinium lead triiodide - methylammonium lead tribromide - caesium lead tribromide (FAPbI3)0.9(MAPbBr3)0.05(CsPbBr3)0.05 (CsFAMA) [81], which have made a significant contribution to increase the power conversion efficiency (PCE) in thin-film photovoltaics [47, 79, 182]. The growth of crystals to this day is performed exclusively from solution [23, 26, 56, 62]. Important preparation methods are the cooling acid-based precursor solution crystallisation [22], the inverse temperature crystallisation (ITC) [62], and the antisolvent vapour-assistant crystallisation (AVC) [137]. In the cooling crystallisation, the precursor salts AX and PbX2 are dissolved in an aqueous halogen-containing acid at high temperatures [56]. Controlled and slow cooling finally results in a supersaturated precursor solution, which leads to spontaneous nucleation of crystal nuclei, followed by subsequent crystal growth. The ITC method is based on the inverse or retrograde solubility of a dissociated perovskite in an organic solvent [23, 64]. With increasing temperature, the solubility of the perovskite decreases and mm-sized crystals can be grown within a few hours [23]. In the AVC method, the precursors are also dissolved in an organic solvent as well [137]. By slow evaporation of a so-called antisolvent [137], the solubility of the perovskite in the now present solvent mixture decreases and it finally precipitates. In addition, there are many other methods with the goal of growing high quality and large crystals in a short period of time [60, 61, 233, 310].},
  subject      = {Perowskit},
  language  = {en}
}
@phdthesis{Puhl2015,
  author    = {Puhl, Sebastian},
  title     = {Methods for protein crystal delivery: Exploring new techniques for encapsulation and controlled release},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-126371},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {More and more newly registered drugs are proteins. Although many of them suffer from instabilities in aqueous media, the most common way of protein drug administration still is the injection of a solution. Numerous protein drugs require frequent administration, but suitable controlled release systems for proteins are rare. Chapter 1 presents current advances in the field of controlled delivery of particulate protein formulations. While the main focus lies on batch crystallized proteins, amorphous particulate proteins are also discussed in this work. The reason is that, on the one hand precipitated protein particles hold some of the advantages of crystalline proteins and on the other hand the physical state of the protein may simply be unknown for many drug delivery systems or semi-crystalline particles have been used. Crystallization and precipitations methods as well as controlled delivery methods with and without encapsulation in a polymeric delivery system are summarized and critically discussed. In chapter 2 a novel way of protein crystal encapsulation by electrospinning is introduced. Electrospinning of proteins has been shown to be challenging via the use of organic solvents, frequently resulting in protein unfolding or aggregation. Encapsulation of protein crystals represents an attractive but largely unexplored alternative to established protein encapsulation techniques because of increased thermodynamic stability and improved solvent resistance of the crystalline state. We herein explore the electrospinning of protein crystal suspensions and establish basic design principles for this novel type of protein delivery system. Poly-ε-caprolactone (PCL) is an excellent polymer for electrospinning and matrix-controlled drug delivery combining optimal processability and good biocompatibility. PCL was deployed as a matrix, and lysozyme was used as a crystallizing model protein. By rational combination of lysozyme crystals with a diameter of 0.7 or 2.1 μm and a PCL fiber diameter between 1.6 and 10 μm, release within the first 24 h could be varied between approximately 10 and 100\%. Lysozyme loading of PCL microfibers between 0.5 and 5\% was achieved without affecting processability. While relative release was unaffected by loading percentage, the amount of lysozyme released could be tailored. PCL was blended with poly(ethylene glycol) and poly(lactic-co-glycolic acid) to further modify the release rate. Under optimized conditions, an almost constant lysozyme release over 11 weeks was achieved. Chapter 3 takes on the findings made in chapter 2 and further modifies the properties of the nonwovens as protein crystal delivery system. Nonwoven scaffolds consisting of poly-ε-caprolactone (PCL), poly(lactic-co-glycolic acid) (PLGA) and polidocanol (PD), and loaded with lysozyme crystals were prepared by electrospinning. The composition of the matrix was varied and the effect of PD content in binary mixtures, and of PD and PLGA content in ternary mixtures regarding processability, fiber morphology, water sorption, swelling and drug release was studied. Binary PCL/PD blend nonwovens showed a PD-dependent increase in swelling of up to 30\% and of lysozyme burst release of up to 45\% associated with changes of the fiber morphology. Furthermore, addition of free PD to the release medium resulted in a significant increase of lysozyme burst release from pure PCL nonwovens from approximately 2\% to 35\%. Using ternary PCL/PD/PLGA blends, matrix degradation could be significantly improved over PCL/PD blends, resulting in a biphasic release of lysozyme with constant release over 9 weeks, followed by constant release with a reduced rate over additional 4 weeks. Based on these results, protein release from PCL scaffolds is improved by blending with PD due to improved lysozyme desorption from the polymer surface and PD-dependent matrix swelling. Chapter 4 gives deeper insight on lysozyme batch crystallization and shows the influences of the temperature on the precipitation excipients. Yet up to now protein crystallization in a pharmaceutical useful scale displays a challenge with crystal size and purity being important but difficult to control parameters. Some of these influences are being discussed here and a detailed description of crystallization methods and the achieved crystals are demonstrated. Therapeutic use of such protein crystals may require further modification of the protein release rate through encapsulation. Silk fibroin (SF) harvested from the cocoons of Bombyx mori is a well-established protein suitable for encapsulation of small molecules as well as proteins for controlled drug delivery. This novel polymer was deployed for as carrier for the model drug crystals. Lysozyme again was used as a crystallizable protein and the effect of process- as well as formulation parameters of batch crystallization on crystal size were investigated using statistical design of experiments. Lysozyme crystal size depended on temperature and sodium chloride and poly(ethylenglycol) concentration of precipitant solution. Under optimized conditions, lysozyme crystals in a size range of approximately 0.3 to 10 µm were obtained. Furthermore, a solid-in-oil-in-water process for encapsulation of lysozyme crystals into SF was developed. Using this process, coating of protein crystals with another protein was achieved for the first time. Encapsulation resulted in a significant reduction of dissolution rate of lysozyme crystals, leading to prolonged release over up to 24 hours.},
  subject      = {Kontrollierte Wirkstofffreisetzung},
  language  = {en}
}